A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

"This is an area in which we haven't had something we felt hopeful about in a while," professor Joseph Schacht said.

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...